TW200624125A - Compositions and methods for increasing HDL and HDL-2b levels - Google Patents
Compositions and methods for increasing HDL and HDL-2b levelsInfo
- Publication number
- TW200624125A TW200624125A TW094100736A TW94100736A TW200624125A TW 200624125 A TW200624125 A TW 200624125A TW 094100736 A TW094100736 A TW 094100736A TW 94100736 A TW94100736 A TW 94100736A TW 200624125 A TW200624125 A TW 200624125A
- Authority
- TW
- Taiwan
- Prior art keywords
- hdl
- compositions
- methods
- levels
- increasing
- Prior art date
Links
- 230000001965 increasing effect Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- WSYRBHQWMXTCHQ-SFIKJRKMSA-N (2s)-n-[(2r)-1-[[(2s)-1-[[(2r)-1-[[(2r)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-[[( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 WSYRBHQWMXTCHQ-SFIKJRKMSA-N 0.000 abstract 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51589103P | 2003-10-29 | 2003-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200624125A true TW200624125A (en) | 2006-07-16 |
Family
ID=34549456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094100736A TW200624125A (en) | 2003-10-29 | 2005-01-11 | Compositions and methods for increasing HDL and HDL-2b levels |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050148556A1 (enExample) |
| EP (1) | EP1684704A2 (enExample) |
| JP (1) | JP2007509965A (enExample) |
| CA (1) | CA2543170A1 (enExample) |
| TW (1) | TW200624125A (enExample) |
| WO (1) | WO2005041878A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| US20080058292A1 (en) * | 2003-10-29 | 2008-03-06 | Raif Tawakol | Method for increasing HDL and HDL-2b levels |
| US20090069275A1 (en) * | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
| WO2008091338A1 (en) * | 2007-01-23 | 2008-07-31 | Reddy Us Therapeutics, Inc. | Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia |
| WO2008100249A1 (en) * | 2007-02-13 | 2008-08-21 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| US20170042821A1 (en) * | 2007-07-01 | 2017-02-16 | Vitalis Llc | Combination tablet with chewable outer layer |
| US8404275B2 (en) | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| WO2009033072A1 (en) * | 2007-09-05 | 2009-03-12 | Raif Tawakol | Compositions and methods for controlling cholesterol levels |
| RU2010151944A (ru) * | 2008-05-20 | 2012-06-27 | Серенис Терапьютикс С.А. (Fr) | Ниацин и нспвс для комбинированной терапии |
| RU2010153904A (ru) * | 2008-06-02 | 2012-07-20 | Др. Редди'С Лабораторис Лтд. (In) | Ниацин-содержащие композиции с модифицированным высвобождением |
| WO2009149058A2 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Modified release niacin formulations |
| EP2770978B1 (en) | 2011-10-28 | 2018-01-10 | Vitalis LLC | Anti-flush compositions |
| WO2014159684A1 (en) * | 2013-03-13 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating or preventing insulin resistance or abnormal levels of circulating lipids in a mammal |
| US10695309B2 (en) * | 2017-03-31 | 2020-06-30 | Western New England University | Sustained-release liothyronine formulations, method of preparation and method of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3312593A (en) * | 1965-03-10 | 1967-04-04 | Carter Prod Inc | Anti-inflammatory compositions of aspirin and niacin |
| US4080472A (en) * | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| WO1996032942A1 (en) * | 1995-04-19 | 1996-10-24 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
| US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| ATE359785T1 (de) * | 1997-07-31 | 2007-05-15 | Kos Life Sciences Inc | Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung |
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
| US7323496B2 (en) * | 1999-11-08 | 2008-01-29 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
| AU2001288294A1 (en) * | 2000-08-21 | 2002-03-04 | Merck And Co., Inc. | Anti-hypercholesterolemic drug combination |
| PE20020453A1 (es) * | 2000-09-27 | 2002-06-06 | Merck & Co Inc | Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos |
| WO2002040448A1 (en) * | 2000-11-20 | 2002-05-23 | Bristol-Myers Squibb Company | Pyridone derivatives as ap2 inhibitors |
-
2004
- 2004-10-29 US US10/977,508 patent/US20050148556A1/en not_active Abandoned
- 2004-10-29 EP EP04817473A patent/EP1684704A2/en not_active Withdrawn
- 2004-10-29 JP JP2006538281A patent/JP2007509965A/ja active Pending
- 2004-10-29 CA CA002543170A patent/CA2543170A1/en not_active Abandoned
- 2004-10-29 WO PCT/US2004/035910 patent/WO2005041878A2/en not_active Ceased
-
2005
- 2005-01-11 TW TW094100736A patent/TW200624125A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2543170A1 (en) | 2005-05-12 |
| US20050148556A1 (en) | 2005-07-07 |
| EP1684704A2 (en) | 2006-08-02 |
| WO2005041878A2 (en) | 2005-05-12 |
| WO2005041878A3 (en) | 2005-09-01 |
| JP2007509965A (ja) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200624125A (en) | Compositions and methods for increasing HDL and HDL-2b levels | |
| IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
| WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| IL162838A0 (en) | Compositions and methods for prevention and treatment peptide-of amyloid- related disorders | |
| TW200731968A (en) | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | |
| TW200745078A (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MY160041A (en) | Compositions and methods for treating parasitic infections | |
| IL175306A0 (en) | Compositions and dosage forms for enhanced absorption | |
| TW200716139A (en) | Methods and compositions for managing psychotic disorders | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| UA91678C2 (en) | Synergism of galactooligosaccharides and polyfructose | |
| IL217713A0 (en) | Compounds and compositions for delivering active agents | |
| TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
| MX2009013779A (es) | Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r. | |
| ZA200702375B (en) | Quinazolines useful as modulators of ion channels | |
| ATE531721T1 (de) | Cyanoaminochinolone als gsk-3-inhibitoren | |
| IL169793A0 (en) | Synergistic compositions and methods for potentiating anti-oxidative activity | |
| MX2009003912A (es) | Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas. | |
| BRPI0411324A (pt) | composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes | |
| ZA200705881B (en) | Formulations and treatments for well-being | |
| MXPA05010388A (es) | Dispositivos, metodos y composiciones para prevenir la restenosis. | |
| ATE399558T1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
| WO2009033078A3 (en) | Compositions and methods for controlling cholesterol levels |